ClinicalTrials.gg

Program

UBT251

A development code. Also written as “UBT251 Injection 4.0 mg”, “UBT251 Injection 6.0 mg” and “UBT251 Injection 2.0 mg”.

In Novo Nordisk's own words, UBT251, a triple agonist of the receptors for GLP-1, GIP and glucagon. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Sleep Apnea, Obstructive · Fatty Liver, led by 2 companies.

Furthest: phase 3, since Jun 9, 202612 company-led studies, 12 open or runningLicense: The United Laboratories → Novo Nordisk, Mar 2025Next primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
The United Laboratories International88 open or runningphase 3since Jun 9, 2026Aug 13, 2025Dec 2026phase 1 · NCT07785934
Novo Nordisk44 open or runningphase 2since Feb 1, 2026Feb 1, 2026Jan 14, 2027phase 2 · NCT07395687
  • Named in Novo Nordisk’s own pipeline as UBT251 (GLP-1/GIP/glucagon tri-agonist), phase 2, as of Nov 5, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 13, 2025First studies: 2 phase 2 studiesNew to The United Laboratories InternationalThe United Laboratories International · NCT07145151, NCT07134335
  2. Feb 1, 2026Novo Nordisk's first study: phase 2 study in OverweightNew to Novo NordiskNovo Nordisk · NCT07395687 · 333 planned · United States, Canada
  3. Jun 9, 20263 phase 3 studiesPhase 3 reachedThe United Laboratories International · NCT07648225, NCT07653477, NCT07659574
  4. Jun 19, 2026Phase 2 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT07668388 · 300 planned · United States, Australia, Germany and more
  5. Jul 13, 20262 phase 1 studiesNovo Nordisk · NCT07710768, NCT07710729
  6. Aug 11, 2026Phase 3 study in Sleep Apnea, ObstructiveThe United Laboratories International · NCT07767942 · 150 planned
  7. Aug 13, 2026Phase 1 study in ObesityThe United Laboratories International · NCT07785934 · 48 planned · China
  8. Sep 1, 2026Phase 3 study in Sleep Apnea, ObstructiveThe United Laboratories International · NCT07806851 · 150 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in ObesityThe United Laboratories International · NCT07785934
  2. Jan 14, 2027Primary completion: phase 2 study in OverweightNovo Nordisk · NCT07395687
  3. Apr 7, 2027Primary completion: phase 1 study in ObesityNovo Nordisk · NCT07710768
  4. Apr 27, 2027Primary completion: phase 1 study in OverweightNovo Nordisk · NCT07710729

TargetBeta

“UBT251, a triple agonist of the receptors for GLP-1, GIP and glucagon”company filing, read by Claude · source

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
retatrutideruleEli Lillyphase 333
HRS-4729Jiangsu HengRui Medicinephase 25

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07806851Sleep Apnea, Obstructive3Not yet recruitingThe United Laboratories InternationalMar 2029150
NCT07785934Obesity · China1RecruitingThe United Laboratories InternationalDec 202648
NCT07767942Sleep Apnea, Obstructive3Not yet recruitingThe United Laboratories InternationalSep 2028150
NCT07710768Obesity · United States1RecruitingNovo NordiskApr 7, 202744
NCT07710729Overweight · Canada1RecruitingNovo NordiskApr 27, 202740
NCT07668388Diabetes Mellitus, Type 2 · United States, Australia, Germany and more2RecruitingNovo NordiskOct 4, 2027300
NCT07659574Diabetes Mellitus, Type 2 · China3RecruitingThe United Laboratories InternationalSep 24, 2027360
NCT07653477Diabetes Mellitus, Type 2 · China3RecruitingThe United Laboratories InternationalFeb 29, 2028956
NCT07648225Obesity · China3Active, not recruitingThe United Laboratories InternationalSep 29, 2027600
NCT07395687Overweight · United States, Canada2RecruitingNovo NordiskJan 14, 2027333
NCT07145151Metabolic Dysfunction-associated Steatohepatitis (MASH) · China2RecruitingThe United Laboratories InternationalJun 4, 2027156
NCT07134335Obesity · China2RecruitingThe United Laboratories InternationalJul 11, 2030180

How it is read

Names in the registry

  • “UBT251”, 13 entries
  • “UBT251 Injection 4.0 mg”, 2 entries
  • “UBT251 Injection 6.0 mg”, 2 entries
  • “UBT251 Injection 2.0 mg”, 1 entry
  • “UBT251 Injection 2.0 mg group”, 1 entry

Codes read as this program: UBT251.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.